OpenOutcrier Posted - 13 hours ago

$NRIX (+4.9% pre) Nurix Therapeutics (NRIX) Receives PRIME Designation from the European Medicines Agency for NX-5948 - SI https://ooc.bz/l/48931

DonCorleone77 Posted - 1 day ago

$NRIX Nurix Therapeutics announces PRIME designation for NX-5948 from EMA Nurix Therapeutics announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degrader of Bruton's tyrosine kinase, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least a BTK inhibitor and a BCL-2 inhibitor. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data.

DominicBerg Posted - 1 day ago

$NMRA $NRIX LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

LewisDaKat Posted - 4 days ago

$NRIX News out Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 https://marketwirenews.com/news-releases/nurix-therapeutics-presents-preclinical-data-from-tw-5258283445262982.html $NRIX

Marco7676 Posted - 5 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $NRIX $CNTA

oaksapollo Posted - 1 week ago

$NRIX looks like Cathie sold https://cathiesark.com/arkg-holdings-of-nrix

insiderbuyingselling Posted - 2 weeks ago

$NRIX new insider selling: 3290 shares. http://insiderbuyingselling.com/?t=NRIX

insiderbuyingselling Posted - 2 weeks ago

$NRIX new insider selling: 5760 shares. http://insiderbuyingselling.com/?t=NRIX

insiderbuyingselling Posted - 10/31/24

$NRIX new insider selling: 3437 shares. http://insiderbuyingselling.com/?t=NRIX

themacromindset Posted - 1 month ago

$NRIX Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

themacromindset Posted - 1 month ago

$NRIX Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

insiderbuyingselling Posted - 1 month ago

$NRIX new insider selling: 3290 shares. http://insiderbuyingselling.com/?t=NRIX

Thestocktraderhubzee Posted - 1 month ago

$NRIX RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $26

FlynancialAnalyst Posted - 1 month ago

$NRIX $1.41B mc $XBI name with a hammer close & remount of 10 wk SMA on volume as price continues to defend key $20 level Short squeeze under way as short float % continues to decline from 23.56% to now 17.78% YTD Pct of all funds long shares at record highs & rising quickly TrendEdge.app/asset/NRIX

LewisDaKat Posted - 1 month ago

News Article $NRIX Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update https://marketwirenews.com/news-releases/nurix-therapeutics-reports-third-quarter-fiscal-2024-7020814358952240.html $NRIX

DonCorleone77 Posted - 1 month ago

$NRIX Nurix Therapeutics reports Q3 EPS (67c), consensus (69c) Reports Q3 revenue $12.59M, consensus $13.25M. "We continue to make great progress and remain focused on execution as we advance our pipeline of wholly owned and partnered programs in oncology, inflammation and immunology," said Arthur Sands, president and chief executive officer of Nurix. "As we approach the end of the year, we are well capitalized and look forward to building further momentum as we head into clinical data readouts in the fourth quarter of 2024 and the initiation of pivotal studies of NX-5948 in 2025."

insiderbuyingselling Posted - 1 month ago

$NRIX new insider selling: 5760 shares. http://insiderbuyingselling.com/?t=NRIX

MKStock75 Posted - 09/27/24

$NRIX Found its bottom. Ready to move up!

oaksapollo Posted - 2 months ago

$NRIX https://www.nurixtx.com/wp-content/uploads/2024/09/Targeted-Protein-Degraders-As-Next-Generation-Antibody-Payloads_Final.pdf

oaksapollo Posted - 2 months ago

$NRIX it went from $24.44 to $23.33. Isn’t that neat. Hopefully $22.22 is not next.

vu_jade Posted - 08/26/24

$NRIX great chart

Shlobby Posted - 08/26/24

$nrix $RYTM going today

StockInvest_us Posted - 3 months ago

Signal alert: $NRIX - PivotPoint bottom https://stockinvest.us/l/3CjYcVmX6k

oaksapollo Posted - 3 months ago

$NRIX dang look at September $25 call volume and pricing. This is definitely headed higher in the next few weeks.

NVDAMillionaire Posted - 07/31/24

$NRIX Nurix Therapeutics, Inc. (NRIX): A Promising Biotech Poised for Significant Growth http://beyondspx.com/2024/07/31/nurix-therapeutics-inc-nrix-a-promising-biotech-poised-for-significant-growth/

Fullratio Posted - 4 months ago

$NRIX debt to equity has surged by 100% year-on-year but it has dropped by 53% since the previous quarter: https://fullratio.com/stocks/nasdaq-nrix/nurix-therapeutics

DonCorleone77 Posted - 4 months ago

$NRIX Nurix Therapeutics price target raised to $34 from $31 at JPMorgan JPMorgan raised the firm's price target on Nurix Therapeutics to $34 from $31 and keeps an Overweight rating on the shares. The company issued an in-line Q2 update following the "impressive" NX-5948 showing at EHA, the analyst tells investors in a research note.

DonCorleone77 Posted - 4 months ago

$NRIX Nurix Therapeutics price target raised to $31 from $20 at Barclays Barclays raised the firm's price target on Nurix Therapeutics to $31 from $20 and keeps an Overweight rating on the shares. The analyst cites increase confidence in the company's BTK following the update degrader data for the target increase.

Fullratio Posted - 4 months ago

$NRIX equity has surged by 120% since the previous quarter and by 43% year-on-year: https://fullratio.com/stocks/nasdaq-nrix/nurix-therapeutics

DonCorleone77 Posted - 4 months ago

$NRIX Nurix Therapeutics price target raised to $15 from $14 at Morgan Stanley Morgan Stanley raised the firm's price target on Nurix Therapeutics to $15 from $14 and keeps an Equal Weight rating on the shares following quarterly results. The firm said in a research note on Friday that there were no major updates with Q2 earnings release.